Evidence map›Paper›PMID 35136147›Full record

ArticleScientific reports2022

Clinical implication of initial intravenous diuretic dose for acute decompensated heart failure.

Kenji Yoshioka, Daichi Maeda, Takahiro Okumura, Keisuke Kida, Shogo Oishi, Eiichi Akiyama, Satoshi Suzuki, Masayoshi Yamamoto, Akira Mizukami, Shunsuke Kuroda and 6 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 2 countries.

Kenji YoshiokaDepartment of Cardiology, Kameda Medical Center, Chiba, Japan.
Daichi MaedaDepartment of Cardiovascular Medicine, Juntendo University, Tokyo, Japan.
Takahiro OkumuraDepartment of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Keisuke KidaDepartment of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan.
Shogo OishiDepartment of Cardiology, Himeji Cardiovascular Center, Hyogo, Japan.
Eiichi AkiyamaDivision of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.
Satoshi SuzukiDepartment of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.
Masayoshi YamamotoCardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Akira MizukamiDepartment of Cardiology, Kameda Medical Center, Chiba, Japan.
Shunsuke KurodaHeart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
Nobuyuki KagiyamaDepartment of Cardiology, The Sakakibara Heart Institute of Okayama, Okayama, Japan.
Tetsuo YamaguchiDepartment of Cardiology, Cardiovascular Center, Toranomon Hospital, Tokyo, Japan.
Tetsuo SasanoDepartment of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Akihiko MatsumuraDepartment of Cardiology, Kameda Medical Center, Chiba, Japan.
Takeshi KitaiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Yuya MatsueDepartment of Cardiovascular Medicine, Juntendo University, Tokyo, Japan. yuya8950@gmail.com.
Kameda Medical Center · JPCleveland Clinic · USFukushima Medical University · JPHyogo Brain and Heart Center · JPJuntendo University · JPNagoya University · JPNational Cerebral and Cardiovascular Center · JPOsaka University of Pharmaceutical Sciences · JPSakakibara Hospital · JPSt. Marianna University School of Medicine · JPTokyo Medical and Dental University · JPToranomon Hospital · JPUniversity of Tsukuba · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although intravenous diuretics is a cornerstone of acute heart failure treatment (AHF), its optimal initial dose is unclear. This is a post-hoc analysis of the REALITY-AHF, a prospective multicentre observational registry of AHF. The initial intravenous diuretic dose used in each patient was categorised into below, standard, or above the recommended dose groups according to guideline-recommended initial intravenous diuretic dose. The recommended dose was individualised based on the oral diuretic dose taken at admission. We compared the study endpoints, including 60-day mortality, diuretics response within six hours, and length of hospital stay (HS). Of 1093 patients, 429, 558, and 106 were assigned to the Below, Standard, and Above groups, respectively. The diuretics response and HS were significantly greater in the Below group than in the Standard group after adjusting for covariates. Kaplan-Meier analysis indicated a significantly higher incidence of 60-day mortality in the Above group than the Standard group. This difference was retained after adjusting for other prognostic factors. Treatment with a lower than guideline-recommended intravenous diuretic dose was associated with longer HS, whereas above the guideline-recommended dose was associated with a higher 60-day mortality rate. Our results reconfirm that the guideline-recommended initial intravenous diuretic dose is feasible for AHF.

Indexed as

RegistriesAdministration, IntravenousAgedAged, 80 and overDiureticsFemaleFurosemideHeart FailureHumansJapanMaleRetrospective StudiesDiureticsFurosemide

Identifiers

PMID35136147
PMCPMC8825846
OpenAlexW4210844630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.